CT
NBIX icon

Clearstead Trust’s Neurocrine Biosciences NBIX Stock Holding History

Clearstead Trust’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01K Buy
6
+2
+50% +$297 ﹤0.01% 936
2026
Q1 		$527 Sell
4
-19
-83% -$2.52K ﹤0.01% 968
2025
Q4 		$3.26K Buy
+23
New +$3.33K ﹤0.01% 840
2023
Q4 		– Sell
-44
Closed -$4.95K – 452
2023
Q3 		$4.95K Buy
+44
New +$4.63K ﹤0.01% 383

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Clearstead Trust's NBIX Position: Q2 2026 in Review

Clearstead Trust increased its Neurocrine Biosciences (NBIX) stake by 50% in Q2 2026, buying an estimated $297 and bringing the position to 6 shares worth $1.01K. The position accounts for ﹤0.01% of the portfolio, ranked #936.

Clearstead Trust first reported a position in NBIX in Q3 2023 and has held it in 4 quarters since. The position peaked at $4.95K in Q3 2023. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Clearstead Trust held 6 shares of Neurocrine Biosciences worth $1.01K as of Q2 2026.
  • Clearstead Trust bought 2 Neurocrine Biosciences shares in Q2 2026, an estimated $297.
  • Neurocrine Biosciences made up ﹤0.01% of Clearstead Trust's portfolio in Q2 2026, its #936 holding.
  • Clearstead Trust first reported a position in Neurocrine Biosciences in Q3 2023 and has held it in 4 quarters since.
  • Clearstead Trust's Neurocrine Biosciences position peaked at $4.95K in Q3 2023.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Clearstead Trust's 13F filing for Q2 2026, filed 6 Aug 2026.